Glutathione‐Sensitive Photosensitizer–Drug Conjugates Target the Mitochondria to Overcome Multi‐Drug Resistance in Cancer
Advanced Science · 2024
DOI: 10.1002/advs.202307765 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Weiguo Song und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Jinan, 250012, China. Hauptthemen laut MEDLINE: Photosensitizing Agents, Glutathione, Drug Resistance, Multiple, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology program of Weifang Medical University, Shandong Traditional Chinese Medicine Science and Technology development plan.
Abstract (Originalsprache)
Multi‐drug resistance (MDR) is a major cause of cancer therapy failure. Photodynamic therapy (PDT) is a promising modality that can circumvent MDR and synergize with chemotherapies, based on the generation of reactive oxygen species (ROS) by photosensitizers. However, overproduction of glutathione (GSH) by cancer cells scavenges ROS and restricts the efficacy of PDT. Additionally, side effects on normal tissues are unavoidable after PDT treatment. Here, to develop organic systems that deliver effective anticancer PDT and chemotherapy simultaneously with very little side effects, three GSH‐sensitive photosensitizer‐drug conjugates (CyR‐SS‐L) are designed and synthesized. CyR‐SS‐L localized in the mitochondria then is cleaved into CyR‐SG and SG‐L parts by reacting with and consuming high levels of intracellular GSH. Notably, CyR‐SG generates high levels of ROS in tumor cells instead of normal cells and be exploited for PDT and the SG‐L part is used for chemotherapy. CyR‐SS‐L inhibits better MDR cancer tumor inhibitory activity than indocyanine green, a photosensitizer (PS) used for PDT in clinical applications. The results appear to be the first to show that CyR‐SS‐L may be used as an alternative PDT agent to be more effective against MDR cancers without obvious damaging normal cells by the combination of PDT, GSH depletion, and chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Jinan, 250012, China.
- School of Pharmacy, Weifang Medical University, Weifang, 261053, China.
- Weifang Synovtech New Material Technology CO., LTD., Weifang, 262700, China.
- Harway Pharma Co., Ltd., Dongying, 254753, China.
- Department of General Practice, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250013, China.
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
Förderung
- Science and Technology program of Weifang Medical University
- Shandong Traditional Chinese Medicine Science and Technology development plan
Zitieren
APA
Song, W., Yang, H., Wang, Y., Chen, S., Zhong, W., Wang, Q., Ding, W., Xu, G., Meng, C., Liang, Y., Chen, Z. S., Cao, S., Wei, L., & Li, F. (2024). Glutathione‐Sensitive Photosensitizer–Drug Conjugates Target the Mitochondria to Overcome Multi‐Drug Resistance in Cancer. Advanced Science. https://doi.org/10.1002/advs.202307765
Vancouver
Song W, Yang H, Wang Y, Chen S, Zhong W, Wang Q, et al. Glutathione‐Sensitive Photosensitizer–Drug Conjugates Target the Mitochondria to Overcome Multi‐Drug Resistance in Cancer. Advanced Science. 2024. doi:10.1002/advs.202307765
BibTeX
@article{Song2024,
author = {Song, Weiguo and Yang, Hekai and Wang, Ying and Chen, Shuzhen and Zhong, Wenda and Wang, Qian and Ding, Wenshuo and Xu, Guangzhao and Meng, Chen and Liang, Ying and Chen, Zhe-Sheng and Cao, Shuhua and Wei, Liuya and Li, Fahui},
title = {Glutathione‐Sensitive Photosensitizer–Drug Conjugates Target the Mitochondria to Overcome Multi‐Drug Resistance in Cancer},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202307765}
}
EUVIMED